Myriad, Epic partner for genetic testing integration
June 24, 2022 -- Myriad Genetics is partnering with Epic to integrate Myriad’s genetic testing line with Epic’s network of physicians and patients. Read More
Illumina launches research test for HRD
June 22, 2022 -- Illumina on Wednesday announced the launch of a next-generation sequencing (NGS)-based research-use-only test for homologous recombination deficiency that it has developed with Merck. Read More
Fountain Health Insurance to cover Grail multicancer test
June 22, 2022 -- Grail’s multicancer early detection (MCED) blood test, Galleri, is being made available to Fountain Health Insurance customers at 100% coverage, the firms announced on Tuesday. Read More
Wearable device, algorithm show early detection promise
June 22, 2022 -- A wearable tracking tool and machine learning algorithm could augment molecular testing for COVID-19 and other conditions and provide an early warning that an infection is on the way before symptoms begin, according to a new study. Read More
Nucleix expands EU label for bladder cancer test
June 22, 2022 -- Liquid biopsy firm Nucleix announced that it has expanded the European Union (EU) label indication of its EpiCheck test, which detects DNA methylation patterns in urine that are linked to urothelial cancer. Read More
Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment
June 22, 2022 -- Biocartis has signed a deal to codevelop a companion diagnostic test (CDx) with AstraZeneca for the pharma firm’s epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment Tagrisso (osimertinib). Read More
Bio-Techne to acquire Namocell
June 22, 2022 -- Bio-Techne has reached a deal to acquire Namocell, a Mountain View, CA-based single cell selection and sorting technology provider. Read More
AstraZeneca, G42 Healthcare aim to collaborate
June 21, 2022 -- Abu Dhabi-based G42 Healthcare has signed a letter of intent with AstraZeneca with the aim of expanding their collaboration into diagnostics and clinical research and providing access to treatments for patients in the United Arab Emirates (UAE) and beyond. Read More
Exact Sciences, Ultima Genomics ink supply agreement
June 21, 2022 -- Exact Sciences and Ultima Genomics on Tuesday announced a long-term supply agreement by which Exact will obtain access to Ultima's next-generation sequencing (NGS) technologies. Read More
Veracyte announces evidence supporting thyroid genomic test
June 20, 2022 -- Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules. Read More